Celltrion Pharm is pursuing a mid-to-long-term investment strategy totaling 2 trillion won to respond to the growing global demand for pre-filled syringes (PFS).

The core of this strategy, disclosed through a regulatory filing on the 2nd, is the phased construction of new PFS production facilities in the Chungcheongbuk-do region. In the first phase, facilities will be built from 2028 to 2032, and in the second phase, additional expansion will be reviewed after 2032 in consideration of global demand trends. The total projected investment is 2 trillion won.

This plan was first unveiled at the 'National Report on the Development Vision for Advanced Industries in the Chungcheong Region' held in Asan-si, Chungcheongnam-do. Celltrion Pharm expects that through this investment, it will secure supply capabilities in the global market and strengthen its competitiveness.

However, the company emphasized that this disclosure is not a confirmed execution plan but rather a mid-to-long-term guideline. It added that the plan may change depending on future market conditions and the business environment, and that once specific investment details are finalized, necessary procedures will be taken in accordance with relevant laws and disclosure regulations.